Services will include the demonstration of protein expression for therapeutic antibody cross-reactivity (TCR), cell signalling pathway intermediates/surrogates, biomarker efficacy/proof of principle/ proof of mechanism studies, pre and post therapy patient biopsy screening, pharmacology studies, bio-similar studies, companion diagnostic studies, IHC assay development of novel antibodies, aptamer staining. We use tissue samples as frozen or FFPE wax blocks and we can provide IHC assay development or transfer-in client’s methods which we will validate and optimise to demonstrate they are fit for purpose.
Histologix uses Ventana Discovery and Benchmark, XT and Ultra automated IHC staining platforms and also multiple LabVision systems.
Histologix can provide multi-staining assays in order to demonstrate two or more targets in the same section. Chromogenic methods are limited to two target while fluorescent method may identify up to four targets.
Histologix provides the Pharmaceutical and Biotechnology industry with specialist pathology services to assist drug development programmes ranging from Discovery, regulatory preclinical safety testing through to clinical trials and include human tissue sourcing, histology, medical and veterinary histopathology, immunohistochemistry, digital pathology and image analysis. These are technologies that have been developed with to meet current and future requirements of targeted therapy.
Through inward investment the services provided by Histologix Ltd use a range of highly sophisticated technologies and platforms aimed at standardising the various processes involved in order to achieve data generation that is consistent, accurate and reproducible and will assist our clients in the development of their drug programmes.
Histologix is a privately owned contract research organisation that provides specialist pathology services for the Pharmaceutical and Biotechnology industry. Set up in 2005 by industry specialists, Histologix is a GLP/GCP accredited, HTA-licenced company with an extensive and impressive track record of successfully delivering a range of IHC/ISH assays to large and small Pharma/Biotechnology companies and is a preferred supplier of these services to a number of companies.
Find out which conference Histologix is exhibiting at, updated news issues and current vacancies.